Showing 5161-5170 of 5771 results for "".
- FDA OKs IncobotulinumtoxinA (Xeomin) First-Line in Blepharospasmhttps://modernod.com/news/fda-oks-incobotulinumtoxina-xeomin-first-line-in-blepharospasm/2476587/The FDA has approved broadening the indication for incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals) as first-line therapy for blepharospasm in adult patients, the manufacturer has announced, as reported in Medscape. Beni
- Glaucoma Research Foundation Kicks off the Catalyst for a Cure Vision Restoration Initiativehttps://modernod.com/news/glaucoma-research-foundation-kicks-off-the-catalyst-for-a-cure-vision-restoration-initiative/2476588/Glaucoma Research Foundation has launched the third phase of its collaborative research program, Catalyst for a Cure. Called “The Catalyst for a Cure Vision Restoration Initiative,” the new phase was kicked off at the organization’s 2019 Annual Dinner on April 23 in San Francisco. The Cata
- FDA Approves Eylea for All Stages of Diabetic Retinopathyhttps://modernod.com/news/fda-approves-eylea-for-diabetic-retinopathy/2476580/Regeneron announced that the FDA has approved Eylea (aflibercept) injection to treat all stages of diabetic retinopathy (DR). The FDA approval of Eylea as a treatment for DR was based on 6-month and 1-year results from PANORAMA, a randomized, multicenter, controlled phase 3 trial that enrolled 40
- ReGenTree Initiates ARISE-3 (Phase 3) Trial for Dry Eye Syndromehttps://modernod.com/news/regentree-initiates-arise-3-phase-3-trial-for-dry-eye-syndrome/2476577/ReGenTree, a joint venture company between GtreeBNT and RegeneRx Biopharmaceuticals, announced that it initiated a randomized, double masked, placebo-controlled phase 3 clinical trial (ARISE-3) for dry eye syndrome on May 10. The objective of the ARISE-3 study
- Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with Omidria Presented at ASCRShttps://modernod.com/news/clinical-study-showing-reduced-incidence-of-cystoid-macular-edema-with-omidria-presented-at-ascrs/2476575/Omeros announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3% decreases the incidence of postoperative cystoid macular edema (CME), a sight-threatening complication of cataract surgery
- Jefferson and Wills Eye Launch World’s First Center Focused on Connections Between the Eye and the Brainhttps://modernod.com/news/jefferson-and-wills-eye-launch-worlds-first-center-focused-on-connections-between-the-eye-and-the-brain/2476574/Thomas Jefferson University, in partnership with Wills Eye Hospital and thanks to the generosity of several prescient philanthropists, has launched the world’s first center focused on the visual signatures of neurological diseases. The William H. Annesley, Jr., MD ’48 EyeBrain Center will explore
- HHS Finalizes Rule Requiring Manufacturers Disclose Drug Prices in TV Ads to Increase Drug Pricing Transparencyhttps://modernod.com/news/hhs-finalizes-rule-requiring-manufacturers-disclose-drug-prices-in-tv-ads-to-increase-drug-pricing-transparency/2476569/On Wednesday, Health and Human Services Secretary Alex Azar announced a final rule from the Centers for Medicare & Medicaid Servi
- Mati Therapeutics Phase 2 Nepafenac Evolute Clinical Trial Results Show Significant Postoperative Pain Reductionhttps://modernod.com/news/mati-therapeutics-phase-2-nepafenac-evolute-clinical-trial-results-show-significant-postoperative-pain-reduction/2476558/Mati Therapeutics announced that it has completed a phase 2 clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute sustained ocular punctal plug drug delivery platform. The trial was a multicenter, randomized, masked evaluation of Nepafenac Evolute
- Thomas Walters, MD, Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019https://modernod.com/news/thomas-walters-md-presents-update-on-nicoxs-ncx-470-phase-2-clinical-study-in-podium-presentation-at-ascrs-2019/2476555/Nicox SA announced that ophthalmology key opinion leader and clinical investigator in the ongoing NCX 470 phase 2 clinical study, Thomas Walters, MD, delivered a podium presentation at the annual ASCRS 2019 meeting in San Diego updating on the progress of the NCX 470 phase 2 clinical study in pat
- Alcon Launches Advancements to the Centurion Vision System at ASCRShttps://modernod.com/news/alcon-launches-advancements-to-the-centurion-vision-system-at-ascrs/2476556/Alcon introduced new phaco technology that is part of the Centurion Vision System, including the Active Sentry Handpiece and Intrepid Hybrid Tip, at the ASCRS annual meeting. These new products, which are designed to improve safety, consistency and control during cataract surgery,